We have used the tetracycline (tet)-regulated system as described previously to evaluate the applicability of controlled gene expression in cancer gene therapy. As a model gene, we used the human interleukin-2 (IL-2) gene, which has been placed under the transcriptional control of the tetO/promoter. Human melanoma cells were transduced by two modified retroviral tet vectors containing the transactivator regulatory unit and the IL-2 gene driven by the tetO/promoter, respectively. In the absence of tet, IL-2 expression in the target cells was stable over several months. IL-2 production was in the range of 40 U/10 6 cells/24 hours. A fine tuning of IL-2 expression could be achieved by culturing the transduced cells with increasing doses of tet, whereby a concentration of 500 ng/mL tet in the culture medium abrogated IL-2 expression. Most importantly for clinical application, IL-2 expression by the transduced melanoma cells could also be regulated in vivo. When nu/nu mice were inoculated with the transduced tumor cells, they failed to develop tumors. Instead, the inhibition of IL-2 expression in the transduced tumor cells by oral administration of tet led to subcutaneous tumor growth; this growth rate was comparable with the growth rate of subcutaneously inoculated untransduced parental cells. The finding demonstrates the applicability of the tet-regulated system in cancer gene therapy.
A high level of expression and the controllable delivery of gene products constitute two important parameters to accomplish effective gene therapy. The choice of an adequate expression vector system could be an important tool to assess the optimal expression of the target gene. A system that answers these questions has been described recently. 1 Target genes are placed under the control of regulatory sequences (tetO) from the tetracycline (tet)-resistance operon of transposon 10. The tet-regulated system is composed of two elements, each of which is carried on a separate plasmid vector. One component, the regulator unit, encodes the transactivator (tTA). tTA is a fusion protein composed of the tet repressor of Escherichia coli and the transcriptional activation domain of the VP16 protein of the herpes simplex virus. The second component, the response unit, is composed of the E. coli-derived tet resistance operon regulatory element (tetO) embedded within a minimal cytomegalovirus (CMV) promoter. Expression of a target gene inserted downstream of the tetO/minimal CMV promoter is dependent upon the tTA, which binds tetO sequences. In the presence of the antibiotic, the binding of the tTA to the tetO promoter is impaired, resulting in shutoff of target gene expression in cultured cells [1] [2] [3] [4] [5] [6] and transgenic mice. [7] [8] [9] [10] In the absence of the antibiotic, expression of the target gene is induced.
The tet-regulated system allows not only a qualitative off-on transition but also a fine tuning of gene expression with different tet concentrations. 1, 11, 12 Regulation is restricted to the target gene, and host genes are not affected. The required tet concentrations seem nontoxic. 1 We have used a retroviral modification of the tetregulated system to evaluate the feasibility of controlled gene expression in tumor therapy. As a model system, we manipulated the expression of the human interleukin-2 (IL-2) gene in the human melanoma cell line MeWo. In the animal model, we could demonstrate the efficacy of IL-2 expression in mounting an antitumor response of tumor cells expressing IL-2, which has been described repeatedly. [13] [14] [15] [16] [17] In the absence of tet, the expression of IL-2 by the tumor cells prevented subcutaneous (s.c.) growth of the melanoma cells in nu/nu mice. Instead, tumor growth was unimpaired when IL-2 expression was abolished by a supply of the antibiotic in the drinking water. This finding demonstrates for the first time the applicability of the retroviral tet-regulated system in cancer gene therapy. The model creates prospects for in vivo manipulation of immunologically and therapeutically relevant genes.
MATERIALS AND METHODS

Cell culture
The retroviral packaging cell lines Bosc23 and PA317, NIH3T3 (mouse embryo fibroblasts), HeLa (human cervix carcinoma cell line), and CTLL-2 (cytotoxic T-lymphocyte line 2) were purchased from the American Type Culture Collection (Manassas, Va). The human melanoma cell line MeWo has been described previously by Bean et al. 18 All cell lines were maintained at 37°C in 5% CO 2 and Dulbecco's modified Eagle's medium (Life Technologies, Eggenstein, Germany) supplemented with 10% fetal bovine sera (Sigma, Deisenhofen, Germany), 1% glutamine, and 1% penicillin-streptomycin (Life Technologies). CTLL-2 cells were cultured in RPMI 1640 medium (Life Technologies) containing 10% fetal bovine sera and 20 international units/mL human recombinant IL-2 (rIL-2) (Chiron, Emeryville, Calif).
Retroviral vector constructs, viral production, and transduction
The retroviral vector constructs are schematically illustrated in Figure 1 . SF6tTA and ECT2pbiIL-2 are based on the retroviral vector SFG (kindly provided by R. Mulligan, Harvard Medical School, Boston, Mass). The plasmid SF6tTA was constructed by inserting the transactivator regulator element tTA from pUHD15-1 1 and the neomycin resistance marker gene. ECT2pbiIL-2 contains the human IL-2 gene, which is controlled by the tetO/promoter. In this construct tetO is flanked by two divergently orientated CMV minimal promoters (the bidirectional promoter, pbi 11 ). The human IL-2 gene and its tetO/promoter are located in antisense orientation relative to the 5Ј long terminal repeat (LTR), so that the human IL-2 gene is driven only by the tetO/promoter. For packaging of the constructed vectors, 10 g of each plasmid DNA was transfected into the helper-free ecotropic packaging cell line Bosc23 by calcium phosphate precipitation as described previously. 19 The virus supernatant of Bosc23 was harvested after 48 hours, passed through a 0.45-m filter, adjusted to 8 g/mL polybrene, and used to transduce the amphotropic packaging cell line PA317.
The PA317 cells transduced with SF6tTA were selected for G418 resistance at a concentration of 400 g/mL. Individual colonies were analyzed for tTA expression using reverse transcriptase-polymerase chain reaction (RT-PCR). Viral titers were tested by their capacity to confer G418 resistance to NIH3T3 cells. The viral supernatant of the producer colony that showed the highest titer (2 ϫ 10 6 colony-forming units/ mL, data not shown) and tTA expression was used to generate MeWo/tTA by the infection of parental MeWo cells. The producer cell line PA317 was transduced with ECT2pbiIL-2, and the virus-containing supernatant was used to infect a clonal population of MeWo/tTA. Because a second selectable marker gene was absent on the ECTpbiIL-2 plasmid, clonal isolates of double transductants were generated by single-cell plating on a 96-well plate. The resulting double transductant MeWo-tTA/IL-2 was cultured in the absence and presence of tet (500 ng/mL) in the culture medium.
Transfection and luciferase assay
NIH3T3 and HeLa cells (5 ϫ 10 5 ) were first transfected with 1 g of the luciferase reporter plasmid pUHD131-1 by calcium phosphate precipitation. 20 At 1 day after transfection, the medium was changed. On the following day, cells were infected with SF6tTA virus supernatant from the Bosc23 packaging cell line (NIH3T3 target cells) or supernatant from the PA317 supernatant (HeLa target cells). At 2 days after infection, cells were harvested for the luciferase assay. Cells were washed in phosphate-buffered saline and subsequently lysed in luciferase extraction buffer (0.1 M potassium phosphate, 2 mM ethylenediaminetetraacetic acid, 0.7 mM Triton X-100, and 1 mM dithiothreitol) at 4°C. Cell lysates were collected from the plate using a cell scraper and centrifuged. Aliquots (30 L) of the supernatant were mixed with 370 L of luciferase reaction buffer containing 25 mM glycylglycine, 1 mM adenosine triphosphate, and 10 mM MgSO 4 and assayed for luciferase activity in a Lumat (Berthold, Wildbad, Germany). D-luciferin was used at 0.5 mM. Luciferase activity was adjusted to the protein content of the lysates using the Bradford assay (BioRad, Munich, Germany).
Determination of IL-2 production by enzyme-linked immunosorbent assay (ELISA)
Supernatants were collected from MeWo-tTA/IL-2 cells seeded at a density of 2 ϫ 10 5 . Culture supernatant was assayed in triplicate for IL-2 production by ELISA. Briefly, 96-well plates coated with an anti-human IL-2 monoclonal antibody were incubated for 1 hour at 37°C with the test samples. After three washes, the plates were incubated for 1 hour with horseradish peroxidase-conjugated goat anti-human IL-2 according to the manufacturer's protocol. The enzymatic reaction was developed with a chromagen substrate, and optical density was measured on an ELISA plate reader.
Determination of IL-2 production by the CTLL-2 bioassay
The biological activity of IL-2 released by the transduced cells was tested with an IL-2-dependent CTLL proliferation assay. Briefly, dilutions of MeWo-tTA/IL-2 culture supernatant (treated with tet or left untreated) were transferred to a 96-well culture plate containing 3 ϫ 10 4 CTLL-2 cells per well. CTLL-2 cells cultured in RPMI 1640 medium or in a known amount of IL-2 were used as negative and positive controls, respectively. After 6 hours, 0.5 Ci of [ 3 H]thymidine was added to each well, and the culture was incubated for an additional 24 hours. Cells were harvested with a cell harvester (Pharmacia, Uppsala, Sweden), and [
3 H]thymidine incorporation was counted in a liquid scintillation counter (LKB, Turku, Finland). A standard IL-2 curve containing known concentrations permitted the quantitation of IL-2 levels.
IL-2 and tTA expression by RT-PCR
Producer cell lines and the double transductant MeWo-tTA/ IL-2 were tested for tTA and IL-2 gene expression. Total RNA was extracted from 2 ϫ 10 5 cells according to Chomczynski and Sacchi. 21 A total of 2 g of RNA was reverse transcribed to cDNA using the standard protocol. 20 cDNA was subjected to PCR amplification. Reactions were performed in 50-L reaction mixtures that contained 50 mM KCl, 20 mM tris(hydroxymethyl)aminomethane-HCl, 1.5 mM MgCl 2 , 15 mM deoxynucleoside triphosphate, 25 pmol of each primer, the template DNA, and 2 U of Taq polymerase. The thermal cycler profile was as follows: 30 cycles of 60 seconds for denaturing at 94°C and 30 seconds for annealing/elongation at 50°C for the IL-2 primers (R&D Systems, Minneapolis, Minn). For tTA PCR, annealing was performed at 58°C for 45 seconds, and elongation was accomplished at 64°C for 1 minute in the 40-cycle profile. The amplified products were electrophoresed in a 1.5% agarose gel.
Provirus integration by genomic PCR
Genomic DNA was isolated by cell lysis in 1% sodium dodecyl sulfate, 200 L proteinase K, 100 mM NaCl, 10 mM tris(hydroxymethyl)aminomethane, and 25 mM ethylenediaminetetraacetic acid at 55°C for 16 hours after DNA isolation; isolation was accomplished by phenol-chloroform extraction and ethanol precipitation. 20 A total of 1 g of DNA was amplified by PCR using tTA and the IL-2 gene-specific primers according to the same protocol as described above.
Tumorigenicity in nu/nu mice
Parental MeWo cells and MeWo-tTA/IL-2 cells (previously cultured in the presence and absence of tet) (5 ϫ 10 6 ) were procured from tissue culture flasks, washed, and injected s.c. into the flanks of congenitally athymic nude mice. The group of mice injected with tet-pretreated MeWo-tTA/IL-2 received 200 g/mL tet dissolved in 5% sucrose supplied in the drinking water, which was exchanged every 3 days. Bidirectional tumor diameters were measured using a caliper at regular intervals for 60 days.
Cytotoxicity assay
The natural killer (NK) activity of spleen cells from nu/nu mice was assayed on MeWo target cells in a 4-hour 51 Cr release assay. For preactivation, spleen cells (3 ϫ 10 6 ) were cultured for 6 days in the presence and the absence of tet together with 3 ϫ 10 5 irradiated (100 Gy) parental MeWo cells, IL-2-transduced MeWo cells, and parental MeWo cells, for which the culture medium contained 20 U of rIL-2.
Target cells were prepared by culturing cells for 2 hours in the presence of 100 Ci of 51 Cr. A total of 10 4 labeled target cells per well were mixed with titrated amounts of effector cells to yield effector to target ratios of 50 -6:1 and were incubated for 4 hours. Plates were centrifuged, and released radioactivity was measured in 100-L aliquots of the supernatants. Maximum release was determined by incubating the target cells with 2% sodium dodecyl sulfate; spontaneous release was measured by incubating the target cells with the culture medium.
RESULTS
Tet-dependent regulation of luciferase activity with the retroviral tTA transactivator construct SF6tTA To test the activity of the retroviral transactivator construct SF6tTA in the tet-dependent regulation system, we used NIH3T3 and HeLa cells as target cells. At 2 days before infection, target cells were transiently transfected with the luciferase reporter plasmid pUHD131-1 by calcium precipitation. NIH3T3 and HeLa cells were then infected with the SF6tTA virus supernatant from the Bosc23 and PA317 packaging cells, respectively, in the presence (500 ng/mL) and absence of tet. The luciferase activity of the pooled cells was determined 2 days thereafter. In the absence of tet, we observed an elevation of luciferase activity of up to ϳ500-fold in both cell lines (Table 1 ). This observation indicated that the tTA gene driven by the internal 5Ј LTR promoter was active. Furthermore, the tet-inducible system, including the retroviral SF6tTA regulator unit in cooperation with a tet promoter response unit, seemed tightly regulated.
Retroviral gene transfer and generation of MeWo cells expressing IL-2 and tTA simultaneously
The retroviral vector constructs that were used to introduce and express the tTA and the human IL-2 gene simultaneously in the MeWo cell line are shown above (Fig 1) . As described in Materials and Methods, we first generated packaging cell lines that produce tTA and IL-2 virus, respectively. The supernatants of the producer cell lines were tested for viral titer and gene expression either by RT-PCR analysis (tTA) or by ELISA and the CTLL-2 bioassay (IL-2). The colonies showing the highest viral titer and gene expression were used to infect the target MeWo cell line. MeWo cells were infected first with the tTA containing virus supernatant. Neomycin-resistant colonies were selected and cloned. Thereafter, tTA ϩ clones were infected with IL-2-containing supernatant.
Clonal isolates of the double transductant MeWotTA/IL-2 clones were analyzed for proviral DNA amplification and gene expression. Amplification of the respective proviral IL-2 and tTA genes is shown for one clone by PCR of genomic DNA samples and by RT-PCR for proviral mRNA (Fig 2) . Untransduced MeWo cells did not express the tTA gene or the IL-2 gene (data not shown).
Tet-regulated expression of IL-2 and dose-dependent expression of IL-2 at different tet concentrations
Several MeWo-tTA/IL-2 clones were cultured in the absence of tet, and IL-2 production was determined by ELISA and by CTLL-2 assay. The amount of IL-2 produced by the different MeWo-tTA/IL-2 clones varied from 5 to 40 U/10 6 cells/24 hours (data not shown). The clone that expressed the highest amount of IL-2 (40 U) was selected for subsequent studies. Transfected MeWotTA/IL-2 cells were then cultured in the presence of increasing doses of tet, and the expression of IL-2 was analyzed by RT-PCR and ELISA. Figure 3 , A and B, shows a gradual reduction of IL-2 expression with an increasing dose of tet. The data indicated that IL-2 expression in the transduced tumor cells could be reduced gradually by increasing concentrations of tet; a complete inhibition of IL-2 expression could be achieved by 100 ng/mL tet.
Exposure to tet interferes with activation of NK cells by IL-2-transduced tumor cells As shown in Table 2 NK/lymphokine activated killer (LAK) activity was significantly increased after the coculture of spleen cells with the transduced MeWo-tTA/ IL-2. By adding tet to the culture medium, spleen cells did not become activated and displayed cytotoxicity values comparable with those obtained after coculture with untransduced MeWo cells. However, tet as such did not influence the activation of NK cells, because NK cells became activated to the same degree in cultures containing exogenous IL-2 or exogenous IL-2 plus tet. This finding demonstrated that the secreted IL-2 is biologically active and that the supply of tet has no toxic effects on NK/LAK cells.
Tumorigenicity in nude mice
Finally, we evaluated the in vivo applicability of the tet system in tumor-bearing mice. It is known that a s.c. injection of 5 ϫ 10 6 parental MeWo cells leads to tumor growth in 100% of nu/nu mice. 22 In the reported experiment, nu/nu mice received a s.c. inoculation of 5 ϫ 10 6 transduced and nontransduced MeWo cells. One group of mice inoculated with transduced MeWo-tTA/IL-2 MeWo-tTA/IL-2 cells was isolated and reverse transcribed; the cDNA was amplified using specific primers for the respective genes IL-2 and glyceraldehyde-3-phosphate dehydrogenase. Amplified products were separated on a 1% agarose gel stained with ethidium bromide. B: IL-2 production was determined with the CTLL-2 bioassay. IL-2 levels were evaluated as U/10 6 cells/24 hours. cells received tet in drinking water, whereas the other group received water without the antibiotic. No tumor growth was observed in the group of animals receiving the transduced MeWo-tTA/IL-2, which underlines the efficacy of the antitumor immune response induced by tumor cells expressing IL-2. The growth rate of MeWotTA/IL-2 when mice received tet in drinking water did not significantly differ from the growth rate of parental MeWo cells (Fig 4) . This result demonstrates that IL-2 production in the injected tumor cells can be switched off in vivo by an oral administration of tet. This finding is particularly worthwhile, considering that the tumor cells were implanted into the subcutis, which is not an easily accessible region.
DISCUSSION
The feasibility of regulating the expression of biologically active substances such as hormones, cytokines, or chemokines could be of great clinical importance in tumor therapy, but also in autoimmune diseases and chronic infections. To explore the possibility of in vivoregulated expression of the cytokine IL-2, we have used the classical two-plasmid tet system as delineated by Gossen and Bujard 1 and modified it as a retroviral system to transduce the tTA gene and the human IL-2 gene simultaneously in the human melanoma cell line MeWo. We could demonstrate regulation of IL-2 expression in vitro as well as in vivo. In the latter situation, IL-2 expression could be regulated systemically (i.e., in a s.c. growing tumor by oral application of tet). In agreement with previous results, we observed neither in vitro nor in vivo leakiness of the binary system. 1, 2, 11 To test the functionality of the new constructed retroviral transactivator construct SF6tTA, we transiently transfected NIH3T3 and HeLa cells. Because there is no retroviral reporter construct available, we had to use the original nonretroviral luciferase reporter plasmid, in which the luciferase reporter gene is placed downstream of the chimeric tetO/CMV minimal promoter. We also had to transiently transfect it before the target cells were infected with the SF6tTA-containing supernatant. The determination of the luciferase activity in the absence of tet revealed up to a 500-fold induction, which was tightly regulated. Because the reporter plasmid was not of a retroviral origin, the induction rate as well as the tight regulation cannot be directly transmitted to the retroviral system. Nonetheless, transient transfection with the retroviral transactivator construct SF6tTA allowed us to prove the functionality of the retroviral tTA vector construct.
When generating the MeWo-tTA/IL-2 cells, we noted that distinct clones produced variable amounts of IL-2, whereby it should be noted that the amount of IL-2 production was a stable feature of the individual clones. All functional studies were pursued with a clone that produced 40 U/10 6 cells/24 hours. This dose has been reported by several groups to be the appropriate range to induce an antitumor immune response. 16, 23 The efficiency of IL-2 production by MeWo-tTA/IL-2 to initiate the activation of NK cells was proven in vitro as well as in vivo. Spleen cells of nu/nu mice exhibited a significantly higher cytotoxic potential against MeWo cells after coculture with transduced MeWo-tTA/IL-2 than after coculture with untransduced MeWo cells. Although a similar increase in cytotoxic activity could be achieved by the addition of exogenous IL-2, the cyto toxic activity of spleen cells cultured with MeWo-tTA/ IL-2 in the presence of tet displayed only background cytolytic activity. The fact that the addition of tet to cultures containing exogenous IL-2 did not influence LAK activation proves that the applied concentration of tet was not toxic. In vivo, the amount of IL-2 expressed by the transduced MeWo cells was sufficient to completely prevent tumor growth, whereas an application of tet in drinking water was sufficient to fully restore tumorigenicity (i.e., in the presence of tet, the transduced MeWo showed a comparable growth rate with untransduced MeWo cells). As demonstrated in vitro and controlled in vivo (data not shown), tet had no affect on NK/LAK activity. Thus, the restoration of tumor growth cannot be assigned to an impaired immune defense, but most likely will be attributable to the switch-off of IL-2 production. It is already known that a supply of tet in drinking water leads to a continuous dissemination of the antibiotic in different tissues, whereby tet is readily absorbed and broadly distributed without toxicity at the concentration needed to regulate the activity of the promoter. 10 This was demonstrated for vascularized tissues such as the liver in transgenic mice. 10 We have proven that the antibiotic also easily accesses nonvascularized tissue, such as a depot of tumor cells in a s.c. pocket. This assumption derives from the observation that the effect of inhibiting IL-2 expression was readily visible already at the start of tumor growth (i.e., at 10 days after application of the tumor cells and tet, respectively).
Thus, although the in vivo applicability of the tet system has already been shown using transgenic expression systems in animals carrying the tTA and the gene of interest [7] [8] [9] [10] or by directly injecting the gene into the tissue, 24, 25 we have demonstrated for the first time the in vivo feasibility of the retroviral tet-regulated system in gene therapy with IL-2 transduced tumor cells in the mouse.
Independent of the discussion for the need for different retroviral expression vectors or promoters to achieve optimal expression of the gene of interest, the described in vivo manipulation of gene expression in transduced tumor cells with the tet-regulated system provides perspectives on gene therapy. The off-on regulation and, even more significant, the fine tuning, could be of advantage in the expression of certain genes for which efficacy is tightly linked to an optimal level of gene expression. Beyond this, the use of a bidirectional promoter 11 allows for the possibility of two different genes being distinctly coregulated.
